Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
Novavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.Build your future with us
Join other passionately curious people who are bringing innovative vaccines to the world
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Ebola virus disease (EVD)
Central Africa, West Africa
EBOV spreads from wild animals to humans and by human-to-human transmission via contact with blood and body fluids or contaminated objects
- During the last half-century, there have been more than 40 outbreaks of EVD in Equatorial Africa
- The largest outbreak so far caused over 28,000 infections and 11,000 deaths between 2013 and 2016
- Case-fatality rate (CFR) is estimated at 40%–50%
- The outbreak cost an estimated $2.2 billion to the economy of Guinea, Liberia, and Sierra Leone in 2015
Ebola virus disease (EVD) is a severe and often lethal disease caused by the Ebola virus (EBOV).1 The virus is transmitted by direct human-to-human contact via blood and body fluids (ie, it is not transferred through a respiratory route like influenza)1,3,4 and mainly affects adults, although infected children under the age of 5 years have a higher risk of dying from the disease.1,3 The virus is also transmitted via the placenta and can result in fetal death.1
What characterizes EVD?
EVD usually begins with a fever and may progress to severe gastrointestinal symptoms, followed by abnormal blood clotting, unexplained hemorrhage, organ failure, and death.1 A small subset of patients with lower viral load develop a robust immune response and recover, although the virus is likely to persist (remain alive and undetected) in their body, possibly in the central nervous system and the urinary and genital organs.1
In these individuals, the virus can become active again and give rise to recurrent disease flare-ups.3 There are similarities between this chronic state of EVD and autoimmune diseases, which are typically characterized by unpredictable flare-ups of symptoms and a long-term impact on the health and well-being of those affected.5
EVD vaccines are urgently needed
The main strategy used to stop EVD outbreaks is the prevention of transmission between people in hospitals and the community.1 Isolation of affected people and contact tracing are crucially important, and a ring vaccination strategy (contacts of infected people are identified and vaccinated) may be an effective solution.1 An anti-EBOV vaccine was successfully tested using a ring vaccination study in 2016.6 Amid concerns about increasing transmission rates, accelerated development of anti-EBOV therapeutics and new and effective EVD vaccines is urgently required.1,4
- Jacob ST, et al. Ebola virus disease. Nat Rev Dis Primers. 2020;6:13.
- Centers for Disease Control and Prevention (CDC). Cost of the ebola epidemic. Available at: https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/cost-of-ebola.html [Accessed 27 Aug 2021].
- Muñoz-Fontela C, McElroy AK. Ebola virus disease in humans: pathophysiology and immunity. Curr Top Microbiol Immunol. 2017;411:141–169.
- Salata C, et al. Ebola virus entry: from molecular characterization to drug discovery. Viruses. 2019;11:274.
- Rojas M, et al. Ebola virus disease: an emerging and re-emerging viral threat. J Autoimmun. 2020;106:102375.
- Gsell P, et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis. 2017;17(12):1276–1284.